Literature DB >> 16733054

PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease.

Gary Landreth1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16733054     DOI： 10.1016/j.expneurol.2006.04.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  20 in total

Review 1.  Role of insulin resistance in Alzheimer's disease.

Authors:  Zhiyou Cai; Ming Xiao; Liying Chang; Liang-Jun Yan
Journal:  Metab Brain Dis       Date:  2014-11-16       Impact factor: 3.584

Review 2.  Roles of AMP-activated protein kinase in Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Keshen Li; Sohel H Quazi; Bin Zhao
Journal:  Neuromolecular Med       Date:  2012-02-26       Impact factor: 3.843

3.  Insulin is differentially related to cognitive decline and atrophy in Alzheimer's disease and aging.

Authors:  Jeffrey M Burns; Robyn A Honea; Eric D Vidoni; Lewis J Hutfles; William M Brooks; Russell H Swerdlow
Journal:  Biochim Biophys Acta       Date:  2011-07-01

Review 4.  Growth hormone/insulin-like growth factor I axis in neurodegenerative diseases.

Authors:  M Gasperi; A E Castellano
Journal:  J Endocrinol Invest       Date:  2010-09       Impact factor: 4.256

Review 5.  The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease.

Authors:  Youngnam N Jin; Gail V W Johnson
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

6.  Alzheimer's disease is type 3 diabetes-evidence reviewed.

Authors:  Suzanne M de la Monte; Jack R Wands
Journal:  J Diabetes Sci Technol       Date:  2008-11

7.  PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia.

Authors:  Weiping Qin; Vahram Haroutunian; Pavel Katsel; Christopher P Cardozo; Lap Ho; Joseph D Buxbaum; Giulio M Pasinetti
Journal:  Arch Neurol       Date:  2009-03

Review 8.  Cognitive dysfunction and diabetes mellitus.

Authors:  Christopher T Kodl; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

9.  Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.

Authors:  Rodrigo A Quintanilla; Youngnam N Jin; Karen Fuenzalida; Miguel Bronfman; Gail V W Johnson
Journal:  J Biol Chem       Date:  2008-07-18       Impact factor: 5.157

10.  Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production.

Authors:  Huaqi Xiong; Debbie Callaghan; Aimee Jones; Douglas G Walker; Lih-Fen Lue; Thomas G Beach; Lucia I Sue; John Woulfe; Huaxi Xu; Danica B Stanimirovic; Wandong Zhang
Journal:  Neurobiol Dis       Date:  2007-11-04       Impact factor: 5.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.